Functional genomics lead to new therapies in follicular lymphoma
about
Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer.Tumor suppressors in follicular lymphoma.Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression.Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing.
P2860
Functional genomics lead to new therapies in follicular lymphoma
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Functional genomics lead to new therapies in follicular lymphoma
@ast
Functional genomics lead to new therapies in follicular lymphoma
@en
Functional genomics lead to new therapies in follicular lymphoma
@nl
type
label
Functional genomics lead to new therapies in follicular lymphoma
@ast
Functional genomics lead to new therapies in follicular lymphoma
@en
Functional genomics lead to new therapies in follicular lymphoma
@nl
prefLabel
Functional genomics lead to new therapies in follicular lymphoma
@ast
Functional genomics lead to new therapies in follicular lymphoma
@en
Functional genomics lead to new therapies in follicular lymphoma
@nl
P2860
P356
P1476
Functional genomics lead to new therapies in follicular lymphoma
@en
P2093
Hans-Guido Wendel
P2860
P356
10.1111/NYAS.12120
P407
P577
2013-07-01T00:00:00Z